Marshall Wace, LLP Verona Pharma PLC Transaction History
Marshall Wace, LLP
- $77.3 Billion
- Q3 2024
A detailed history of Marshall Wace, LLP transactions in Verona Pharma PLC stock. As of the latest transaction made, Marshall Wace, LLP holds 12,812 shares of VRNA stock, worth $687,235. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,812
Previous 13,500
5.1%
Holding current value
$687,235
Previous $195,000
88.72%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding VRNA
# of Institutions
168Shares Held
68.7MCall Options Held
704KPut Options Held
685K-
Perceptive Advisors LLC New York, NY6.32MShares$339 Million4.75% of portfolio
-
Nea Management Company, LLC Timonium, MD5.58MShares$300 Million12.27% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.01MShares$269 Million2.01% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx4.22MShares$226 Million2.52% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.55MShares$190 Million14.95% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $3.27B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...